drugset / Trial / NCT04427774
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor
Timeline
- Start
- 2020-06-29
- Primary completion
- 2021-02-08
- Completion
- 2021-04-27
Outcome
Outcome not reported
Stopped: “Policy change, not for security reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | — | Intravenous |
| Subject | Surufatinib | Small molecule | — | Oral |
Indications
No indication recorded.